Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amgen Inc. is currently conducting a Phase 1b clinical study titled ‘A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Subjects With High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer After Definitive Therapy.’ The study aims to assess the safety and tolerability of Xaluritamig, a promising treatment for patients with high-risk biochemical recurrent nonmetastatic castration-sensitive prostate cancer.
The intervention being tested is Xaluritamig, administered as an intravenous infusion. This experimental drug is given over six cycles, with each cycle lasting 28 days, to determine its effectiveness and safety in the target patient group.
The study follows an interventional design with a single-group model, meaning all participants receive the same treatment without any masking. The primary purpose of the study is treatment-focused, seeking to establish Xaluritamig’s potential benefits for prostate cancer patients.
The study began on September 23, 2024, with the latest update provided on June 24, 2025. These dates are crucial as they mark the study’s progress and ongoing recruitment, reflecting Amgen’s commitment to advancing cancer treatment.
This clinical update could positively influence Amgen’s stock performance by showcasing their dedication to innovative cancer therapies. Investors may view this as a strategic move to strengthen Amgen’s position in the oncology market, potentially impacting competitor dynamics.
The study is currently recruiting, with further updates available on the ClinicalTrials portal.